Amgen Inc (AMGN)
269.98
+0.60
(+0.22%)
USD |
NASDAQ |
Apr 26, 16:00
270.05
+0.07
(+0.03%)
After-Hours: 20:00
Amgen Accounts Receivable (Quarterly): 7.268B for Dec. 31, 2023
Accounts Receivable (Quarterly) Chart
Historical Accounts Receivable (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 7.268B |
September 30, 2023 | 6.145B |
June 30, 2023 | 5.83B |
March 31, 2023 | 5.736B |
December 31, 2022 | 5.563B |
September 30, 2022 | 5.326B |
June 30, 2022 | 5.327B |
March 31, 2022 | 5.077B |
December 31, 2021 | 4.895B |
September 30, 2021 | 4.765B |
June 30, 2021 | 4.479B |
March 31, 2021 | 4.423B |
December 31, 2020 | 4.525B |
September 30, 2020 | 4.094B |
June 30, 2020 | 5.366B |
March 31, 2020 | 5.009B |
December 31, 2019 | 4.057B |
September 30, 2019 | 3.606B |
June 30, 2019 | 3.801B |
March 31, 2019 | 3.771B |
December 31, 2018 | 3.58B |
September 30, 2018 | 3.441B |
June 30, 2018 | 3.504B |
March 31, 2018 | 3.633B |
December 31, 2017 | 3.237B |
Date | Value |
---|---|
September 30, 2017 | 3.404B |
June 30, 2017 | 3.56B |
March 31, 2017 | 3.248B |
December 31, 2016 | 3.165B |
September 30, 2016 | 3.186B |
June 30, 2016 | 3.078B |
March 31, 2016 | 3.078B |
December 31, 2015 | 2.995B |
September 30, 2015 | 2.901B |
June 30, 2015 | 2.779B |
March 31, 2015 | 2.548B |
December 31, 2014 | 2.546B |
September 30, 2014 | 2.355B |
June 30, 2014 | 2.697B |
March 31, 2014 | 2.514B |
December 31, 2013 | 2.697B |
September 30, 2013 | 2.67B |
June 30, 2013 | 2.674B |
March 31, 2013 | 2.528B |
December 31, 2012 | 2.518B |
September 30, 2012 | 2.696B |
June 30, 2012 | 2.708B |
March 31, 2012 | 2.988B |
December 31, 2011 | 2.896B |
September 30, 2011 | 2.725B |
Accounts Receivable Definition
Account used to record sales made "on account", meaning that the company has made a sale but has not collected payment. When company collects cash as payment, the corresponding account receivable is decreased.
Accounts Receivable (Quarterly) Range, Past 5 Years
3.606B
Minimum
Sep 2019
7.268B
Maximum
Dec 2023
5.015B
Average
5.009B
Median
Mar 2020
Accounts Receivable (Quarterly) Benchmarks
Gilead Sciences Inc | 4.66B |
Johnson & Johnson | 14.87B |
Eli Lilly and Co | 9.090B |
Merck & Co Inc | 10.35B |
Vertex Pharmaceuticals Inc | 1.563B |